New 17P data somewhat disappointing

Article

-->

17-alpha hydroxyprogesterone (17P) may reduce preterm deliveries, but it doesn't seem to reduce perinatal deaths. At least that's the conclusion of a large study reported at this year's Annual Clinical Meeting. To reach that conclusion, University of Miami investigators examined a database of high-risk patients with prior preterm deliveries (PTD) (n=699) and current singleton gestations who had been receiving weekly 250 mg IM injections of 17P, or observation (n=880). While those on progesterone delivered at 36.2 weeks (+/- 4.2), compared to 35.5 weeks ( +/- 4.2) (P<0.001), there were no significant differences between the groups when researchers looked at the incidence of stillbirths, neonatal deaths, miscarriages at less than 24 weeks, or total perinatal deaths.

Gonzalez-Quentero VH, Smarkusky L, Carter J, et al. 17-alpha-hydroxyprogesterone caproate: perinatal mortality and pregnancy outcomes. Obstet Gynecol. 2007;109(suppl):7S.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Ousseny Zerbo, PhD, highlights benefits of influenza vaccination during pregnancy | Image Credit: divisionofresearch.kaiserpermanente.org.
Michael Ussher, PhD, highlights the benefits of vaping over smoking in pregnancy | Image Credit: sgul.ac.uk.
Neal Barnard, MD, FACC, highlights AMA's new breast cancer prevention guidelines | Image Credit: pcrm.org.
Zachary Wagner, PhD, discusses the harms of bias in reproductive care | Image Credit: ornsife.usc.edu.
Related Content
© 2025 MJH Life Sciences

All rights reserved.